Adage Capital Partners’s Rhythm Pharmaceuticals RYTM Stock Holding History

Adage Capital Partners’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$44.1M	Sell	397,000 -328,744	-45%	-$29.7M	0.06%	309
2026 Q1	$63.1M	Buy	725,744 +104,159	+17%	+$10.1M	0.1%	213
2025 Q4	$66.5M	Buy	621,585 +77,585	+14%	+$8.23M	0.1%	196
2025 Q3	$54.9M	Buy	544,000 +203,000	+60%	+$18.8M	0.09%	220
2025 Q2	$21.5M	Buy	+341,000	New	+$20.9M	0.04%	435
2023 Q4	–	Sell	-43,815	Closed	-$1M	–	921
2023 Q3	$1M	Buy	+43,815	New	+$981K	﹤0.01%	765
2020 Q2	–	Sell	-25,000	Closed	-$381K	–	794
2020 Q1	$381K	Hold	25,000	–	–	﹤0.01%	707
2019 Q4	$574K	Hold	25,000	–	–	﹤0.01%	693
2019 Q3	$540K	Hold	25,000	–	–	﹤0.01%	702
2019 Q2	$550K	Hold	25,000	–	–	﹤0.01%	693
2019 Q1	$685K	Buy	+25,000	New	+$718K	﹤0.01%	669
2018 Q4	–	Sell	-25,000	Closed	-$729K	–	746
2018 Q3	$729K	Buy	+25,000	New	+$790K	﹤0.01%	698

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Adage Capital Partners's RYTM Position: Q2 2026 in Review

Adage Capital Partners reduced its Rhythm Pharmaceuticals (RYTM) stake by 45% in Q2 2026, selling an estimated $29.7M and leaving 397,000 shares worth $44.1M. The position accounts for 0.06% of the portfolio, ranked #309.

Adage Capital Partners first reported a position in RYTM in Q3 2018 and has held it in 12 quarters since. The position peaked at $66.5M in Q4 2025. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

Adage Capital Partners held 397,000 shares of Rhythm Pharmaceuticals worth $44.1M as of Q2 2026.
Adage Capital Partners sold 328,744 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $29.7M.
Rhythm Pharmaceuticals made up 0.06% of Adage Capital Partners's portfolio in Q2 2026, its #309 holding.
Adage Capital Partners first reported a position in Rhythm Pharmaceuticals in Q3 2018 and has held it in 12 quarters since.
Adage Capital Partners's Rhythm Pharmaceuticals position peaked at $66.5M in Q4 2025.
304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.